These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 15780832

  • 1. Cardiovascular hazard and non-steroidal anti-inflammatory drugs.
    Wang D, Wang M, Cheng Y, Fitzgerald GA.
    Curr Opin Pharmacol; 2005 Apr; 5(2):204-10. PubMed ID: 15780832
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E.
    Ann Clin Lab Sci; 2005 Apr; 35(4):347-85. PubMed ID: 16254252
    [Abstract] [Full Text] [Related]

  • 3. Coxibs, non-steroidal anti-inflammatory drugs and cardiovascular risk.
    Hermann M, Ruschitzka F.
    Intern Med J; 2006 May; 36(5):308-19. PubMed ID: 16650196
    [Abstract] [Full Text] [Related]

  • 4. The pharmacology of selective inhibition of COX-2.
    Grosser T.
    Thromb Haemost; 2006 Oct; 96(4):393-400. PubMed ID: 17003913
    [Abstract] [Full Text] [Related]

  • 5. The cardiovascular pharmacology of COX-2 inhibition.
    Fries S, Grosser T.
    Hematology Am Soc Hematol Educ Program; 2005 Oct; ():445-51. PubMed ID: 16304418
    [Abstract] [Full Text] [Related]

  • 6. Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.
    Maillard M, Burnier M.
    Expert Opin Drug Saf; 2006 Jan; 5(1):83-94. PubMed ID: 16370958
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW, van der Bij S, Welsing P, Kuipers EJ, Herings RM.
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [Abstract] [Full Text] [Related]

  • 9. [Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases].
    Jukić A, Kaliterna DM, Radić M.
    Reumatizam; 2010 May; 57(1):26-8. PubMed ID: 20941937
    [Abstract] [Full Text] [Related]

  • 10. COX-2 selective nonsteroidal anti-inflammatory drugs: current status.
    Mahajan A, Sharma R.
    J Assoc Physicians India; 2005 Mar; 53():200-4. PubMed ID: 15926604
    [Abstract] [Full Text] [Related]

  • 11. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now?
    Spektor G, Fuster V.
    Nat Clin Pract Cardiovasc Med; 2005 Jun; 2(6):290-300. PubMed ID: 16265533
    [Abstract] [Full Text] [Related]

  • 12. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D.
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [Abstract] [Full Text] [Related]

  • 13. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular thromboembolic adverse effects associated with cyclooxygenase-2 selective inhibitors and nonselective antiinflammatory drugs.
    Joshi GP, Gertler R, Fricker R.
    Anesth Analg; 2007 Dec; 105(6):1793-804, table of contents. PubMed ID: 18042885
    [Abstract] [Full Text] [Related]

  • 15. Cyclooxygenase-2 inhibitors, nonsteroidal anti-inflammatory drugs, and cardiovascular risk.
    Vardeny O, Solomon SD.
    Cardiol Clin; 2008 Nov; 26(4):589-601. PubMed ID: 18929233
    [Abstract] [Full Text] [Related]

  • 16. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB, West CR, Borer JS, Gorelick PB, Lavange L, Pan SX, Weiner E, Verburg KM.
    Am J Cardiol; 2007 Jan 01; 99(1):91-8. PubMed ID: 17196469
    [Abstract] [Full Text] [Related]

  • 17. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E, Nedjar H.
    Rheumatology (Oxford); 2007 Mar 01; 46(3):435-8. PubMed ID: 17255138
    [Abstract] [Full Text] [Related]

  • 18. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
    Rahme E, Nedjar H, Bizzi A, Morin S.
    Aliment Pharmacol Ther; 2007 Nov 15; 26(10):1387-98. PubMed ID: 17892525
    [Abstract] [Full Text] [Related]

  • 19. Cyclooxygenase-2 inhibitors: what went wrong?
    James MJ, Cleland LG.
    Curr Opin Clin Nutr Metab Care; 2006 Mar 15; 9(2):89-94. PubMed ID: 16477171
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
    Hermann M, Ruschitzka F.
    Ann Med; 2007 Mar 15; 39(1):18-27. PubMed ID: 17364448
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.